Global Acromegaly Treatment Market Report and Forecast 2023-2031

Global Acromegaly Treatment Market Report and Forecast 2023-2031

Global Acromegaly Treatment Market Outlook

The global acromegaly treatment market size attained a value of USD 1.61 billion in 2022. The market is likely to witness further growth at a CAGR of 7.65% during the forecast period of 2023-2031 to attain a value of approximately USD 3.12 billion by 2031. The growth of the market can be attributed to the rising awareness about the disorder among healthcare professionals and patients.

Acromegaly: Introduction and Epidemiology

Acromegaly is a rare hormonal disorder that occurs due to the overproduction of growth hormone (GH) by the pituitary gland. The prevalence of acromegaly varies across different regions of the world, with an estimated global prevalence of 60 cases per million population.

Acromegaly typically affects adults between the ages of 30 and 50, although it can occur at any age. The disorder affects both men and women equally. However, some studies have suggested a slightly higher prevalence in women.

The prevalence of acromegaly is highest in certain regions of the world, such as Southern Europe and Latin America, where it is estimated to be as high as 100-130 cases per million population. In contrast, the prevalence is lower in North America and Asia, where it is estimated to be around 40-60 cases per million population.

There are no known lifestyle habits that increase the risk of developing acromegaly. However, certain medical conditions such as multiple endocrine neoplasia type 1 (MEN1) and Carney complex can increase the risk of developing the disorder.

In terms of prognosis, acromegaly can lead to significant morbidity and mortality if left untreated. The most common complications of acromegaly include cardiovascular disease, diabetes mellitus, sleep apnea, and osteoarthritis. However, with appropriate treatment, the long-term outlook for individuals with acromegaly is generally favourable.

In conclusion, acromegaly is a rare hormonal disorder that predominantly affects adults between the ages of 30 and 50. The prevalence of the disorder varies across different regions of the world, with higher prevalence rates in certain regions of Southern Europe and Latin America.

Global Acromegaly Treatment Market Segmentations

Market Breakup by Diagnosis Type

• GH and IGF-I Measurement
• Growth Hormone Suppression Test
• Imaging
• Spine x-ray
• MRI of the brain, including the pituitary gland
• Echocardiogram
• Colonoscopy
• Others

Market Breakup by Treatment Type

• Medication
• Somatostatin analogues
• Dopamine agonists
• Growth hormone antagonist
• Others
• Radiation Therapy
• Surgery
• Others

Market Breakup by Diseases Type

• Ectopic Acromegaly
• Acromegaly Due to Growth Hormone

Market Breakup by Route of Administration

• Oral
• Parentals
• Others

Market Breakup by Treatment Centres

• Hospitals
• Specialty Clinics
• Homecare Settings
• Rehabilitation Centers
• Others

Market Breakup by Treatment Channel

• Public
• Private

Market Breakup by Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Market Breakup by Region

North America

• United States of America
• Canada

Europe

• United Kingdom
• Germany
• France
• Italy
• Others

Asia Pacific

• China
• Japan
• India
• ASEAN
• Australia
• Others

Latin America

• Brazil
• Argentina
• Mexico
• Others

Middle East and Africa

• Saudi Arabia
• United Arab Emirates
• Nigeria
• South Africa
• Others

Global Acromegaly Treatment Market Scenario

The global market for acromegaly treatment is expected to grow significantly in the coming years. The market is primarily driven by the increasing prevalence of the disorder, the rising awareness about the disorder among healthcare professionals and patients, and the development of new and innovative treatment options.

Somatostatin analogues are the most commonly used drugs for the treatment of acromegaly and are expected to continue to dominate the market during the forecast period. However, GH receptor antagonists and dopamine agonists are expected to gain traction in the coming years due to their improved efficacy and safety profiles.

Geographically, the market is expected to experience significant growth in North America and Europe due to the high prevalence of acromegaly in these regions and the presence of well-established healthcare infrastructure. However, the Asia Pacific region is expected to witness the highest growth rate due to the increasing prevalence of the disorder and a growing demand for effective treatment options.

Key Players in the Global Acromegaly Treatment Market

The report gives an in-depth analysis of the key players involved in the global acromegaly market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• F. Hoffmann-La Roche Ltd.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Pfizer Inc.
• GlaxoSmithKline plc.
• Novartis AG
• Merck & Co., Inc.
• Allergan
• AstraZeneca
• Johnson & Johnson Private Limited
• Hikma Pharmaceuticals PLC.
• Bristol-Myers Squibb Company
• Bayer AG
• Boehringer Ingelheim International GmbH.
• Dr. Reddy's Laboratories Ltd.
• Gilead Sciences, Inc.
• Eli Lilly and Company
• AbbVie Inc.
• Lupin